Sesen Bio
Cambridge
About Sesen Bio
Sesen Bio is a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on their Targeted Protein Therapeutics (TPTs) platform. Their TPTs genetically combine targeting antibody fragments with cytotoxic protein payloads to create a single fusion protein through Eleven's proprietary one-step manufacturing process.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $163.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jun 2018)
- Ticker: nasdaq:SESN
- Website: sesenbio.com
- Phone: +1 617-871-9911
Industries & Categories
Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/sesen-bio-218054 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.